Syngene Expands Strategic Research Collaboration with Bristol Myers Squibb Through 2035

Syngene International has expanded its research collaboration with Bristol Myers Squibb through 2035. The agreement covers the drug development lifecycle, including discovery, translational sciences, pharmaceutical development, and manufacturing. Syngene will provide seamless progression from research to commercialization, reinforcing its position as a strategic partner. The expansion marks the next phase of growth, enabling the company to plan for the future with a decade-long horizon.